Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 2Lymphoma, B-Cell 2Lymphoma 2Waldenstrom Macroglobulinemia 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1

Interventions

Rituximab 44Cyclophosphamide 38Prednisone 26Doxorubicin 25Vincristine 20Magnetic Resonance Spectroscopy 20Lenalidomide 19Specimen Handling 18Gemcitabine 18Biopsy 15polatuzumab vedotin 14Oxaliplatin 14glofitamab 12obinutuzumab 11ibrutinib 10Etoposide 10CT-P10 9fludarabine 8Dexamethasone 8prednylidene 7pembrolizumab 7deltacortene 7Prednisolone 7N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 7venetoclax 6tafasitamab 6acalabrutinib 6fludarabine phosphate 5R-CHOP protocol 5Immunotherapy, Adoptive 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Lymphoma, Large B-Cell, Diffuse × loncastuximab tesirine × 90 days × Clear all
NCT05453396 2026-05-11

Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

University of Washington

Phase 2 Recruiting
20 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT05672251 2026-05-11

Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

City of Hope Medical Center

Phase 2 Recruiting
36 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04384484 2026-04-28

LOTIS 5

ADC Therapeutics S.A.

Phase 3 Active not recruiting
440 enrolled
Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡